Objective: We aimed to evaluate if the Mean Platelet Volume (MPV) is an acute phase reactant in non-healing wounds, by analyzing its correlation with Erythrocyte Sedimentation Rate (ESR). Method: Our study was carried out in a descriptive type with the participation of patients with non-healing wounds. The laboratory data and characteristics of the patients were accessed retrospectively, and the obtained data were recorded in the data recording form. Results: The sample group consisted of 92 patients with non-healing wounds. 26.9% of the patients with non-healing wounds had pressure sores, 37.6% of them had diabetic foot wounds, 18.3% had non-healing wounds developed after trauma, and 17.2% had necrotizing fasciitis. The average age of the patients was 53.22±19.13, and the average length of stay in the hospital was 108.98±18.78 (min 3 months, max 6 months) days. The MPV value, which was found to be high in the early stages of non-healing wounds, decreased after the wound was completely healed. When the MPV value was compared to ESR, an acute phase reactant, a positive and strong statistically significant correlation was found between MPV and ESR based on the result of this correlation analysis (r=0.256, p<0.01). Conclusion: MPV can be used as a marker, just like ESR, in the presence of non-healing wounds. MPV value can be measured with blood taken into the complete blood count. However, an extra blood sample and a different tube are required for ESR. Using MPV value instead of ESR will provide savings in terms of cost and labor.

Aim: This study aimed to determine the incidence of hypophosphatemia and evaluate anemia parameters following intravenous iron sucrose (IS) and iron carboxymaltose (FCM) therapy in patients diagnosed with iron deficiency anemia (IDA). Methods: This retrospective study included 108 patients aged 18– 67 who were diagnosed with IDA and received either FCM or IS therapy. The patients were divided into two groups: iron sucrose (n=55, 51%) and ferric carboxymaltose (n=53, 49%). We collected and analysed data on patient demographics, doses of FCM and IS, and laboratory parameters including serum phosphorus, ferritin, total iron-binding capacity (TIBC), iron, and haemoglobin (Hg) values. Results: The pre-treatment blood phosphorus levels were significantly lower in the IS group than in the FCM group (p = 0.029). Following intravenous iron treatment, the TIBC and phosphorus levels were higher in the IS group compared to the FCM group (p = 0.011 and p < 0.001, respectively). The ferritin levels were significantly higher in the FCM group compared to the IS group (p = 0.002). Conclusion: It is important to be aware that hypophosphatemia may occur after intravenous iron therapy for iron deficiency anemia. Therefore, phosphate levels should be monitored closely following treatment. Furthermore, it would appear that hypophosphatemia is more prevalent following FCM therapy compared to IS.

Objective: The purpose of this study is to assess the olfactory system of patients with T2DM using the cranial magnetic resonance imaging (MRI) method. Method: This is a retrospective case–control study in which a group of T2DM patients and a control group were compared. The results of the examinations of the olfactory systems of the patients by cranial MRI were transferred to a data collection form. Descriptive statistical methods, chi‐squared tests, the Mann–Whitney U test, and Spearman's correlation coefficient were used to analyze the data. Results: It was determined that 66.7% of the case group were women, the mean age of the patients in the group was 52.50 ± 7.41, and their mean T2DM diagnosis duration was 6.48 ± 3.18 years. There were statistically significant differences between the case and control groups in terms of their olfactory bulb volume (OBV), olfactory tract length (OTL), and olfactory sulcus depth (OS) values. Longer T2DM durations and elevated HbA1c levels were significantly associated with structural disorders of the olfactory system ( p < 0.01). Conclusion: A longer duration of T2DM and elevated HbA1c levels trigger the structural disorders of the olfactory system. In comparison to healthy controls, we identified prominent changes in the olfactory bulb volumes, olfactory tract lengths, and olfactory sulcus depths of T2DM patients. This reveals the need for T2DM patients to pay more attention to their diet and insulin treatment. Similarly, olfactory dysfunction in T2DM patients should be carefully monitored by clinicians.

This study aims to examine lung transplant recipients’ adherence to the drug regimen, and gastrointestinal disorders that they suffered. The sample of this descriptive and cross-sectional research comprised 58 lung transplant recipients who were discharged from the hospital. In the data collection process, we used the socio-demographic and health-related characteristics information form, the immunosuppressant therapy adherence scale, the Morisky medication adherence scale, and the gastrointestinal symptom rating scale. In the data analysis, we utilized descriptive statistical methods, Mann Whitney U and Spearman correlation. The mean age of lung transplant recipients was 44.37 ± 9.18 years, and of all participant lung transplant recipients, 53.4% were female, 65.5% were struggling with comorbidities, 51.7% underwent lung transplantation >5 years ago, 17.2% were oxygen-dependent, 51.7% had coughs, 31% had dyspnea, and 29.3% had hypertension. All lung transplant recipients were using corticosteroids while 91.4% of them were using tacrolimus. We found statistically significant connections between the use of mycophenolate mofetil and constipation, between the use of tacrolimus and diarrhea, and between the use of amlodipine and gastroesophageal reflux in lung transplant recipients. Lung transplant recipients’ adherence to immunosuppressants and other medications was above average. The medications used were associated with gastrointestinal symptoms. The findings of our study highlight that lung transplant recipients’ in-home care and treatment needs continue.

Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.

Objectives: Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting the axial skeleton and peripheral joints, causing pain, stiffness, and reduced function. Monitoring disease activity is crucial, but no specific laboratory markers reflect disease activity in AS. This study evaluated the relationship between pan immune-inflammation value (PIIV) and disease activity in AS. Materials and Methods: This study included patients with AS fulfilling the modified New York classification criteria. Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP). Data included demographic, clinical, treatment, and laboratory variables, including C-reactive protein (CRP), erythrocyte sedimentation rate, blood counts, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio, systemic immune-inflammation index (SII), and PIIV. Results: Of 64 patients (female/male: 22/42), 38 (59.4%) had active disease according to BASDAI. The active group showed higher PIIV, ASDAS-CRP, platelet count, PLR, and SII, and lower hemoglobin than the inactive group. PIIV correlated with BASDAI, ASDAS-CRP, and inflammatory markers including CRP, erythrocyte sedimentation rate, neutrophil, platelet, and monocyte counts, neutrophil-to-lymphocyte ratio, PLR, monocyte-to-lymphocyte ratio, and SII. Conclusion: PIIV was significantly higher in active AS and correlated with disease activity and inflammatory markers. It may support disease activity assessment in AS.